Julie M. Vose, MD, MBA, on Basket Trials
2016 Pan Pacific Lymphoma ConferenceJulie M. Vose, MD, MBA, of the University of Nebraska Medical Center, discusses this evolution of clinical trials, and using genomic methods to direct therapy.
Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, discusses this evolution of clinical trials, and using genomic methods to direct therapy.
Steven P. Treon, MD, PhD, of the Dana-Farber Cancer Institute, discusses the question of what is the best upfront therapy for lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia.
Susan M. O’Brien, MD, of the University of California, Irvine, discusses the challenges of treating older patients with acute lymphoblastic leukemia and lymphoma, and the positive results with newer regimens using blinatumomab and inotuzumab.
David G. Maloney, MD, PhD, of Fred Hutchinson Cancer Research Center, discusses the efficacy of chimeric antigen receptor (CAR) T cells for lymphoma and their toxicity.
Wyndham H. Wilson, MD, PhD, of the National Cancer Institute, discusses the molecular underpinnings of diffuse large B-cell lymphoma and targeted treatments.
Richard I. Fisher, MD, of Fox Chase Cancer Center-Temple Health, discusses this rare disease––with features between classical Hodgkin lymphoma and primary mediastinal large B-cell lymphoma––and reviews the clinical data on treatment.